Cost-effectiveness of highly active antiretroviral therapy for HIV infection in Taiwan

Journal of the Formosan Medical Association

Volumn 106, Issue 8, 2007, Pages 631-640

  Fang, Chi Tai ^a   Chang, Yu Yin ^b   Hsu, Hsu Mei ^c   Twu, Shiing Jer ^b,c   Chen, Kow Tong ^d   Chen, Ma Yuan ^a   Huang, Loreen Y L ^b   Hwang, Jing Shiang ^e   Wang, Jung Der ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Executive Yuan ^*  (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

Author keywords

Cost effectiveness; HAART; Health policy; Highly active antiretroviral therapy; HIV infection

Indexed keywords

ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NATIONAL HEALTH INSURANCE; OPPORTUNISTIC INFECTION; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SURVIVAL RATE; TAIWAN; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

EID: 34548512041     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(08)60020-0     Document Type: Article

References (42)

1. Fang CT, Hsu SM, Twu SJ, et al. Decreased HIV transmission after a policy of providing free access to highly active anti-retroviral therapy in Taiwan. J Infect Dis 2004;190:879-85.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
3. Fang CT, Chang Y'~ Hsu HM, et al. Life expectancy of patients with newly diagnosed HIV infection in the era of highly active antiretroviral therapy. QJM 2007;100:97-105.
4. Infectious Diseases Society of Taiwan/Taiwan AIDS Society Consensus Conference. Guidelines for the use of antiretroviral agents in HIV infections in Taiwan. J Microbial Immunol Infect 2001;34:224-6.
5. Centers for Disease Control and Prevention. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR 2002;51(No.RR-7):11-7.
6. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, October, 2006. Available at: http://aidsinfo.nih.gov/Guidelines [Date accessed: March 27, 2007]
7. Montvale NJ. Drug topics red book. Medical Economics, 1998.
8. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001;344:824-31.
9. Chen YM, Lan YC, Lai SF, et al. HIV-1 CRF07_BC infections, injecting drug users, Taiwan. Emerg Infect Dis 2006;12: 703-5.
10. Chen YM, Kuo SH. HIV-1 in Taiwan. Lancet 2007;369: 623-5.
11. Sendi PP, Bucher HC, Harr T, et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. AIDS 1999;13:1115-22.
12. Beck EJ, Mandalia S, Gaudreault M, et al. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001. AIDS 2004;18:2411-8.
13. Badri M, Maartens G, Mandalia S, et al. Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med 2006;3:e4.
14. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Eivaluation of Health Care Programmes, 3rd edition. Oxford: Oxford University Press, 2005.
15. Law on the Prevention and Control of AIDS, Taiwan, 1990. Available at: http://203.65.72.83/En/das/ShowPublication.ASP?RecNo=965 [Date accessed: May 9, 2005]
16. Hsieh GY, Chen PC, Wang JD. Verification and correction of error for death registration data of the Department of Health R.O.C. between 1980 and 1997. Taiwan J Public Health 2002;21:329-38.
17. Lee ET, Go OT. Survival analysis in public health research. Annu Rev Public Health 1997;18:105-34.
18. Hwang JS, Wang JD. Monte Carlo estimation of extrapolation of quality-adjusted survival for follow-up studies. Stat Med 1999;18:1627-40.
19. Hwang JS, Wang JD. Integrating health profile with survival for quality of life assessment. Qual Life Res 2004;13: 1-10.
20. Wang JD. Basic Principles and Practical Applications in Epidemiological Research. Singapore: World Scientific, 2002:151.
21. Ho WL, Lin KH, Wang JD, et al. Financial burden of national health insurance for treating patients with transfusion-dependent thalassemia in Taiwan. Bone Marrow Transplant 2006;37:569-74.
22. Ho JJ, Hwang JS, Wang JD. Life expectancy estimations and the determinants of survival after 15 years of follow-up on 81,249 workers with permanent occupational disabilities. Scand J Work Environ Health 2006;32: 91-9.
23. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. London: Chapman & Hall, 1993.
24. Fang CT, Hsiung PC, Yiu CF, et al. Validation of World Health Organization Quality of Life instrument in patients with HIV infection. Qual Life Res 2002;11:753-62.
25. Hsiung PC, Fang CT, Chang YY, et al. Comparison of WHOQOL-BREF and SF-36 in patients with HIV infection. Qual Life Res 2005;14:141-50.
26. Bala MV, Wood LL, Zarkin GA, et al. Are health states "timeless"? The case of the standard gamble method. J Clin Epidemiol 1999:52:1047-53.
27. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146: 473-81.
28. Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998;13:716-7.
29. Evans C, Tavakoli M, Crawford B. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manage Sci 2004;7:43-9.
30. Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004;7:518-28.
31. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006;332: 699-703.
32. World Health Organization. WTO Agreements and Public Health: A joint Study by the WHO and WTO Secretariat. Geneva: WTO/WHO, 2002.
33. Wilson JF. Building African AIDS care from the ground up. Ann Intern Med 2003;139:157-60.
34. Teixeira PR, Vitoria MA, Barcarolo J. Antiretroviral treatment in resource-poor settings: the Brazilian experience. AIDS 2004;18(Suppi 3):S5-7.
35. Parsons TD, Braaten AJ, Hall CID, Robertson KR. Better quality of life with neuropsychological improvement on HAART. Health Qual Life Outcomes 2006;4:11.
36. Liu C, Ostrow D, Detels R, et al. Impacts of HIV infection and HAART use on quality of life. Qual Life Res 2006; 15:941-9.
37. Gebo KA, Fleishman JA, Moore RD. Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr 2005; 40:609-16.
38. Bernell SL, Shinogle JA. The relationship between HAART use and employment for HIV-positive individuals: an empirical analysis and policy outlook. Health Policy 2005;71: 255-64.
39. Halkitis PN, Shrem MT, Zade DD, Wilton L. The physical, emotional and interpersonal impact of HAART: exploring the realities of HIV seropositive individuals on combination therapy. J Health Psychol 2005;10:345-58.
40. McCormick AW, Walensky RP, Lipsitch M, et al. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis 2007; 44:1115-22.
41. Bayer R, Levine C, Wolf SM. HIV antibody screening. An ethical framework for evaluating proposed programs. JAMA 1986;256:1768-74.
42. Warwick Z. The influence of antiretroviral therapy on the uptake of HIV testing in Tutume, Botswana. Int J STD AIDS 2006;17:479-81.